The behavioral effects of the calcium agonist BAY K 8644 in the mouse: Antagonism by the calcium antagonist nifedipine |
| |
Authors: | Gordon T. Bolger Ben Avi Weissman Phil Skolnick |
| |
Affiliation: | (1) Laboratory of Bioorganic Chemistry, National Institutes of Health, Bldg. 4, Room 212, 20205 Bethesda, MD, USA;(2) National Institute of Arthritis, Diabetes, and Digestive, National Institutes of Health, 20205 Bethesda, MD, USA;(3) Kidney Diseases, National Institutes of Health, 20205 Bethesda, MD, USA |
| |
Abstract: | ![]() Summary Mice injected with the calcium agonist BAY K 8644 (2–4 mg/kg, i. p.) displayed profound behavioral changes including ataxia, decreased motor activity, Straub tail, arched back, limb clonus and tonus, and an increased sensitivity to auditory stimulation. BAY K 8644 significantly impaired rotorod performance in mice with an ED50 of 0.8 mg/kg. The behavioral effects of BAY K 8644 were antagonized by nifedipine, but not by the non-dihydropyridine calcium channel antagonist verapamil or the -adrenoceptor antagonist prazosin. Further, the actions of BAY K 8644 were not mimicked by the -adrenoceptor agonist methoxamine at doses up to 4.5 mg/kg. These observations, coupled with the findings that BAY K 8644 is a potent, competitive inhibitor of [3H]nitrendipine binding to the dihydropyridine binding site in mouse brain (Ki=7.0×10–9M), suggests that BAY K 8644 may produce its behavioral actions via an interaction with the DHP binding site, which has been linked to the control of calcium flux across membranes in peripheral tissues. |
| |
Keywords: | BAY K 8644 Calcium agonist Nifedipine Calcium channels Dihydropyridine binding site |
本文献已被 SpringerLink 等数据库收录! |
|